Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer ( Poseidon Study）

Hunan Province Tumor Hospital1 site in 1 country70 target enrollmentMarch 24, 2020

ConditionsNon-small Cell Lung Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Non-small Cell Lung Cancer
Sponsor: Hunan Province Tumor Hospital
Enrollment: 70
Locations: 1
Primary Endpoint: PFS
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

Detailed Description

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.

Registry

clinicaltrials.gov

Start Date

March 24, 2020

End Date

March 24, 2025

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Hunan Province Tumor Hospital

Responsible Party

Principal Investigator

Yongchang Zhang

professor

Hunan Province Tumor Hospital

Eligibility Criteria

Inclusion Criteria

•≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
•RET Fusion Positive
•First Diagnosis and Treatment
•Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody